Unlock instant, AI-driven research and patent intelligence for your innovation.

Preparation method and applications of pyrrolopyrimidine compound

A compound, unsubstituted technology, applied in the application field of immunosuppressants, which can solve problems such as combined immunodeficiency disease

Active Publication Date: 2017-08-29
CINKATE PHARMA INTERMEDIATES
View PDF11 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

For JAK3 selectivity, children with JAK3 kinase deficiency may have severe combined immunodeficiency disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and applications of pyrrolopyrimidine compound
  • Preparation method and applications of pyrrolopyrimidine compound
  • Preparation method and applications of pyrrolopyrimidine compound

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0084] The preparation of formula I-b compound

[0085] The present invention also provides a method for preparing a representative compound I-b of the compound of formula I, said method comprising the steps of:

[0086]

[0087] In an inert solvent, the compound of formula II is reacted with the compound of formula III to obtain the compound of formula I-b, wherein, R 1 ’ is defined as above.

[0088] In another preferred embodiment, the inert solvent is selected from the group consisting of dichloromethane, chloroform, 1,2-dichloroethane, toluene, xylene, or combinations thereof.

[0089] In another preferred example, the molar ratio of the compound of formula II to the compound of formula III is 0.5-2:0.5-2; preferably about 1:1.

[0090] In another preferred example, the reaction time is 1-15h, preferably 2-10h, more preferably 0.5-5h.

[0091] In another preferred example, the reaction is carried out under an organic base catalyst.

[0092] In another preferred emb...

Embodiment 1

[0114] Example 1 Preparation of compound 1: N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)phenyl-1,4-diamine

[0115]

[0116] Weigh 1.53 g of 4-chloropyrrolopyrimidine, 4.6 g of N-methyl-p-nitroaniline, and 4M HCl in dioxane and heat in 40 mL of dioxane at 130° C. overnight. The mixture was cooled to room temperature and concentrated to dryness under reduced pressure. The residue was slurried with ethyl acetate until most of the N-methyl-p-nitroaniline disappeared, and the resulting solid was dissolved in a mixture of methanol and triethylamine (1.5 eq), added to silica gel, and concentrated to dryness under reduced pressure. The residue was separated by silica gel column chromatography and eluted with dichloromethane / methanol=30 / 1 system to obtain 1.4 g of N-methyl-N-(4-nitrophenyl)-7H-pyrrolo[2,3-d ] Pyrimidin-4-amine, yield 91.5%.

[0117] 11g of the above product, 10% Pd / C, was stirred in a methanol closed system equipped with a hydrogen balloon until the raw materials...

Embodiment 2

[0121] Example 2 Preparation of compound 2: 5-methyl-isoxazole-{4-methyl-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-amino]-phenyl}-4- Amide

[0122] Weigh 100mg N-methyl-N-(7H-pyrrolo[2,3-d]pyrimidine-4-)phenyl-1,4-diamine and 16mg DMAP respectively in a three-necked flask, add 20mL dichloromethane Stir to dissolve, cool to about -20°C, and add 100 mg of triethylamine dropwise to the reaction solution. Then, 103 mg of 5-methylisoxazole-4-carbonyl chloride dissolved in 5 mL of dichloromethane solution was slowly added dropwise. After the dropwise addition, the mixture was slowly raised to room temperature and reacted for 5 hours. The reaction was monitored by TLC until the end. Add 20mL of water to quench the reaction, separate and extract, wash the aqueous phase with dichloromethane 3 times, combine the organic phase, anhydrous Na 2 SO 4 Dry and separate by silica gel column chromatography, eluting with ethyl acetate / n-hexane = 1 / 1 system to obtain 72 mg of the product with a yield ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a preparation method and applications of a pyrrolopyrimidine compound, particularly a compound represented by a formula I or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the salt, a preparation method of the compound, and applications of the compound as an immunosuppressive agent. The formula I is defined in the specification.

Description

technical field [0001] The invention relates to a pyrrolopyrimidine compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing the compound or the salt, a preparation method thereof and an application as an immunosuppressant. Background technique [0002] JAK1 has a key role in multiple cytokine and growth factor signaling pathways, and JAK1 dysregulation can cause or contribute to disease or lead to inflammatory responses. For example, in rheumatoid arthritis, activation of interleukin-6 has pro-inflammatory effects, and direct or indirect antagonism of IL-6 through JAK1 inhibition would provide clinical benefit. [0003] Selective inhibitors of JAK1 have multiple therapeutic benefits over less selective inhibitors relative to other JAK kinases. Selectively for JAK2, a variety of important cytokines and growth factors signal through JAK2 including, for example, erythropoietin (EPO) and thrombopoietin (TPO). Reduced TPO signaling will r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/04A61K31/519A61P29/00A61P19/02A61P37/02A61P25/00A61P37/06A61P3/10A61P1/00A61P1/16A61P17/06A61P17/00A61P27/02A61P37/08A61P11/06A61P21/00
CPCC07D487/04A61K31/519A61P29/00A61P19/02A61P37/02A61P25/00A61P37/06A61P3/10A61P1/00A61P1/16A61P17/06A61P17/00
Inventor 刘娜包丽霞魏哲鹏周裕峰荣彬赵立辉肖飞
Owner CINKATE PHARMA INTERMEDIATES
Features
  • R&D
  • Intellectual Property
  • Life Sciences
  • Materials
  • Tech Scout
Why Patsnap Eureka
  • Unparalleled Data Quality
  • Higher Quality Content
  • 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More